A large array of human monoclonal antibodies to type 1 from combinatorial libraries of asymptomatic seroposit

Proceedings of the National Academy of Sciences of the Unite

88, 10134-10137

DOI: 10.1073/pnas.88.22.10134

Citation Report

#	Article	IF	Citations
1	Level of School Counselor Actualizing and Student Perception of Guidance Services: Further Validation of the Personal Orientation Inventory. Educational and Psychological Measurement, 1976, 36, 501-504.	1.2	4
2	Human Antibody Effector Function. Advances in Immunology, 1992, 51, 1-84.	1.1	240
3	Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4457-4461.	3.3	372
5	Some Highlights of Virus Research in 1991. Journal of General Virology, 1992, 73, 2487-2501.	1.3	0
6	Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9339-9343.	3.3	270
7	Byâ€"Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling. Nature Biotechnology, 1992, 10, 779-783.	9.4	317
8	Human combinatorial antibody libraries to hepatitis B surface antigen.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3175-3179.	3.3	162
9	Adapting antibodies for clinical use.. BMJ: British Medical Journal, 1992, 305, 1348-1352.	2.4	14
10	Principles of antibody therapy.. BMJ: British Medical Journal, 1992, 305, 1424-1429.	2.4	18
11	The human antibody library.. BMJ: British Medical Journal, 1992, 304, 585-586.	2.4	7
12	Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10164-10168.	3.3	171
13	A binary plasmid system for shuffling combinatorial antibody libraries.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10026-10030.	3.3	79
14	Human Monoclonal Antibodies: Achievement and Potential. Hospital Practice (1995), 1992, 27, 67-74.	0.5	4
15	Rescue and expression of human immunoglobulin genes to generate functional human monoclonal antibodies. Human Antibodies, 1992, 3, 146-152.	0.6	11
16	In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 3576-3580.	3.3	289
17	Clonal Patterns in the Human Immune Response to HIV-1 Infection. International Reviews of Immunology, 1992, 9, 1-13.	1.5	25
18	Peptide display on filamentous phage capsids An new powerful tool to study protein-ligand interaction. FEBS Letters, 1992, 307, 66-70.	1.3	38
19	Phophabs: Antibody-phage-alkaline phosphatase conjugates for one step ELISA's without immunization. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 1073-1078.	1.0	21

#	Article	IF	Citations
20	Original and artificial antibodies. Nature, 1992, 357, 201-202.	13.7	66
21	Antibodies from libraries. Nature, 1992, 359, 782-783.	13.7	38
22	Building Antibodies from their Genes. Immunological Reviews, 1992, 130, 41-68.	2.8	146
23	Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors and in vitro Maturation Systems. Immunological Reviews, 1992, 130, 109-124.	2.8	44
24	Immunotherapy of AIDS. Current Opinion in Biotechnology, 1992, 3, 650-655.	3.3	1
25	Antibody expression in bacteriophage systems: The future of monoclonal antibodies?. Current Opinion in Biotechnology, 1992, 3, 474-480.	3.3	8
26	Fabulous Fabs from phage. Current Biology, 1992, 2, 507-509.	1.8	2
27	Recent advances in phage display. Current Opinion in Biotechnology, 1993, 4, 526-530.	3.3	65
28	Searching Sequence Space to Engineer Proteins: Exponential Ensemble Mutagenesis. Nature Biotechnology, 1993, 11, 1548-1552.	9.4	21
29	Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production. Gene, 1993, 137, 69-75.	1.0	203
30	Monoclonal antibodies from combinatorial libraries. Accounts of Chemical Research, 1993, 26, 405-411.	7.6	39
31	Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops. Gene, 1993, 128, 103-109.	1.0	62
32	Building antibodies from their genes. Revue Francaise De Transfusion Et D'hemobiologie: Bulletin De La Societe Nationale De Transfusion Sanguine, 1993, 36, 19-47.	0.5	3
33	Novel Approaches to the Preparation and Use of Monoclonal Antibodies. Transfusion Medicine Reviews, 1993, 7, 25-36.	0.9	2
34	Recombinant antibodies: back to the future. Australian and New Zealand Journal of Medicine, 1993, 23, 393-402.	0.5	0
35	Combinatorial Libraries. International Reviews of Immunology, 1993, 10, 153-163.	1.5	5
36	The New Antibody Technologies. Advances in Applied Microbiology, 1993, 38, 149-209.	1.3	2
37	Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4141-4145.	3.3	172

#	Article	IF	Citations
38	Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2527-2531.	3.3	64
39	A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7538-7542.	3.3	225
40	Human Antibodies to HIV-1 by Recombinant DNA Methods. Chemical Immunology and Allergy, 1993, 56, 112-126.	1.7	7
41	Expression and characterization of recombinant anti-Rh(D) antibodies on filamentous phage: a model system for isolating human red blood cell antibodies by repertoire cloning. Blood, 1994, 83, 2334-2344.	0.6	51
42	Human monoclonal Fab fragments from a combinatorial library prepared from an individual with a low serum titer to a virus. Human Antibodies, 1994, 5, 3-8.	0.6	16
43	Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 1386-1390.	3.3	127
45	Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 1994, 38, 1507-1514.	1.4	99
46	Human Antibodies from Combinatorial Libraries. Advances in Immunology, 1994, 57, 191-280.	1.1	192
47	Bacteriophage epitope libraries. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 1-6.	1.4	2
48	Heterogeneity of combinatorial human autoantibodies against PDC-E2 and biliary epithelial cells in patients with primary biliary cirrhosis. Hepatology, 1994, 20, 574-583.	3.6	44
49	Human anti-IgE antibodies by repertoire cloning. European Journal of Immunology, 1994, 24, 1200-1207.	1.6	46
50	Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen. Nature Biotechnology, 1994, 12, 899-903.	9.4	173
51	Surface display of antibodies. Biotechnology Advances, 1994, 12, 539-555.	6.0	21
52	Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science, 1994, 266, 1024-1027.	6.0	1,080
53	The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3710-3714.	3.3	46
54	Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 355-359.	3.3	98
55	An Improved Phage Display Antibody Cloning System Using Newly Designed PCR Primers Optimized for Pfu DNA Polymerase. Journal of Biochemistry, 1995, 117, 1218-1227.	0.9	25
56	The molecular structure of human antibodies specific for the human immunodeficiency virus. Journal of Clinical Immunology, 1995, 15, 17-26.	2.0	15

#	Article	IF	Citations
57	Generation of Rabbit Monoclonal Antibody Fragments from a Combinatorial Phage Display Library and Their Production in the Yeast Pichia pastoris. Nature Biotechnology, 1995, 13, 255-260.	9.4	114
58	Polyclonal Preparations of Anti-Tetanus Toxoid Antibodies Derived from a Combinatorial Library Confer Protection. Nature Biotechnology, 1995, 13, 683-685.	9.4	3
59	Engineering recombinant antibodies for immunotherapy. Cell Biophysics, 1995, 27, 47-61.	0.4	20
60	Recombinant Antibodies in Bioactive Peptide Design. Journal of Biological Chemistry, 1995, 270, 6628-6638.	1.6	15
61	A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. Blood, 1995, 86, 4430-4436.	0.6	92
62	Human autoantibody recognition of DNA.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2529-2533.	3.3	124
63	Peptide and protein display on the surface of filamentous bacteriophage. Biotechnology Annual Review, 1995, 1, 149-183.	2.1	38
64	Analysis of the Binding of Pro-urokinase and Urokinase-Plasminogen Activator Inhibitor-1 Complex to the Low Density Lipoprotein Receptor-related Protein Using a Fab Fragment Selected from a Phage-displayed Fab Library. Journal of Biological Chemistry, 1995, 270, 11770-11775.	1.6	19
65	Expression of an anti-Pseudomonas aeruginosa lipopolysaccharide core recombinant antibody in Escherichia coli. Journal of Endotoxin Research, 1995, 2, 53-61.	2.5	3
66	Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. Immunotechnology: an International Journal of Immunological Engineering, 1995, 1, 1-19.	2.4	68
67	Human monoclonal Fab fragments specific for viral antigens from combinatorial IgA libraries. Immunotechnology: an International Journal of Immunological Engineering, 1995, 1, 21-28.	2.4	15
68	VH shuffling can be used to convert an Fv fragment of anti-hen egg lysozyme specificity to one that recognizes a T cell receptor Vî±. Molecular Immunology, 1995, 32, 147-156.	1.0	24
69	A review: Cloning of human antibodies by phage display. Clinical Immunology Newsletter, 1996, 16, 69-79.	0.1	0
70	A model phage display subtraction method with potential for analysis of differential gene expression. FEBS Letters, 1996, 391, 71-75.	1.3	28
71	The role of antibodies in respiratory viral immunity. Seminars in Virology, 1996, 7, 273-283.	4.1	12
72	Antibodies against HIV-1 from Phage Display Libraries: Mapping of an Immune Response and Progress towards Antiviral Immunotherapy. Chemical Immunology and Allergy, 1996, 65, 18-56.	1.7	4
73	Circumventing tolerance to generate autologous monoclonal antibodies to the prion protein.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7279-7282.	3.3	112
74	Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Human Antibodies, 1996, 7, 97-105.	0.6	69

#	Article	IF	Citations
75	Human Antibody Responses to HIV Type 1 Glycoprotein 41 Cloned in Phage Display Libraries Suggest Three Major Epitopes Are Recognized and Give Evidence for Conserved Antibody Motifs in Antigen Binding. AIDS Research and Human Retroviruses, 1996, 12, 911-924.	0.5	81
76	Humoral Immune Response to Immunocomplexed HIV Envelope Glycoprotein 120. AIDS Research and Human Retroviruses, 1996, 12, 901-909.	0.5	28
77	Antibody Binding Sites. Advances in Protein Chemistry, 1996, 49, 329-450.	4.4	24
78	Combinatorial Antibodies Against Human Malignant Melanoma. Hybridoma, 1997, 16, 11-16.	0.9	24
79	Recombinant Human Monoclonal Antibody IgG1b12 Neutralizes Diverse Human Immunodeficiency Virus Type 1 Primary Isolates. AIDS Research and Human Retroviruses, 1997, 13, 575-582.	0.5	82
80	Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Lineâ€“adapted HIV-1 Neutralization. Journal of Experimental Medicine, 1997, 186, 1287-1298.	4.2	124
81	Summary of Antibody Workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. Journal of Infectious Diseases, 1997, 176, 549-559.	1.9	54
82	Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8110-8115.	3.3	27
83	Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 9326-9331.	3.3	41
84	High affinity human antibodies by phage display. Human Antibodies, 1997, 8, 155-168.	0.6	23
85	A vaccine for HIV type 1: The antibody perspective. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10018-10023.	3.3	214
86	Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries 1 1Edited by F. E. Cohen. Journal of Molecular Biology, 1997, 267, 684-695.	2.0	57
87	A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform 1 1Edited by M. Yaniv. Journal of Molecular Biology, 1997, 273, 614-622.	2.0	333
88	The Current Status of Heterocyclic Combinatorial Libraries. Chemical Reviews, 1997, 97, 449-472.	23.0	576
89	Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries. AIDS Research and Human Retroviruses, 1997, 13, 1549-1559.	0.5	38
90	INTRACELLULAR ANTIBODIES (INTRABODIES) FOR GENE THERAPY OF INFECTIOUS DISEASES. Annual Review of Microbiology, 1997, 51, 257-283.	2.9	114
91	A Novel Approach to Human Anti-HLA mABs Production: Use of Phage Display Libraries. Human Immunology, 1997, 57, 19-26.	1.2	7
92	Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrobial Agents and Chemotherapy, 1997, 41, 1521-1530.	1.4	566

#	Article	IF	Citations
93	Human Monoclonal Fab Fragments Recovered from a Combinatorial Library Bind Specifically to the Platelet HPA-1a Alloantigen on Glycoprotein IIbâ€"IIIa. Vox Sanguinis, 1997, 72, 52-60.	0.7	6
94	Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Medicine, 1997, 3, 1389-1393.	15.2	262
95	Methodology for selection of human antibodies to membrane proteins from a phage-display library. Journal of Immunological Methods, 1997, 204, 193-203.	0.6	27
96	A Human IgG1 (b12) Specific for the CD4 Binding Site of HIV-1 Neutralizes by Inhibiting the Virus Fusion Entry Process, but b12 Fab Neutralizes by Inhibiting a Postfusion Event. Virology, 1997, 233, 313-326.	1.1	56
97	Anti-inflammatory therapies: application of molecular biology techniques in intensive care medicine. Intensive Care Medicine, 1997, 23, 718-731.	3.9	42
98	IgG rheumatoid factors isolated by the surface-displaying phage library technique. Immunogenetics, 1997, 45, 301-310.	1.2	10
99	Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunology Letters, 1997, 57, 105-112.	1.1	65
100	Human Monoclonal Fab Fragments Recovered from a Combinatorial Library Bind Specifically to the Platelet HPA-1a Alloantigen on Glycoprotein IIb-IIIa. Vox Sanguinis, 1997, 72, 52-60.	0.7	24
101	Creating and engineering human antibodies for immunotherapy. Advanced Drug Delivery Reviews, 1998, 31, 5-31.	6.6	52
102	Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments. Hepatology, 1998, 28, 810-814.	3.6	51
103	Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. European Journal of Immunology, 1998, 28, 4177-4187.	1.6	28
104	The human immune response to red blood cell antigens as revealed by repertoire cloning. Immunologic Research, 1998, 17, 239-251.	1.3	12
105	Surface plasmon resonance biosensors as a tool in antibody engineering. Biosensors and Bioelectronics, 1998, 13, 653-663.	5.3	43
106	Strategies for selection of antibodies by phage display. Current Opinion in Biotechnology, 1998, 9, 102-108.	3.3	237
107	Sequence and Specificity Analysis of Recombinant Human Fab Anti-Rh D Isolated by Phage Display. Vox Sanguinis, 1998, 75, 278-287.	0.7	30
108	Anti-CD34+ fabs generated against hematopoietic stem cells in HIV-derived combinatorial immunoglobulin library suggest antigen-selected autoantibodies fn2 fn2Research supported by Grant AG00537 from the National Institutes of Health, Bethesda, and by the nato International Scientific Exchange Programme, Brussels.. Molecular Immunology, 1998, 35, 955-964.	1.0	6
109	Selection of recombinant anti-HuD Fab fragments from a phage display antibody library of a lung cancer patient with paraneoplastic encephalomyelitis. Journal of Neuroimmunology, 1998, 82, 200-209.	1.1	34
110	Antibody phage display technology and its applications. Immunotechnology: an International Journal of Immunological Engineering, 1998, 4, 1-20.	2.4	455

#	Article	IF	Citations
111	The Therapeutic Potential of Intracellular Antibodies. BioDrugs, 1998, 9, 179-185.	2.2	0
112	Probing the natural antibody repertoire by combinatorial cloning of IgM and IgD isotypes in phage display vectors. Research in Virology, 1998, 149, 321-325.	0.7	2
113	Direct Selection for Catalysis from Combinatorial Antibody Libraries Using a Boronic Acid Probe:Â Primary Amide Bond Hydrolysis. Journal of the American Chemical Society, 1998, 120, 2211-2217.	6.6	71
114	A Combinatorial Phage Display Library for the Generation of Specific Fab Fragments Recognizing Human Spermatozoa and Inhibiting Fertilizing Capacity In Vitro1. Biology of Reproduction, 1998, 59, 1180-1186.	1.2	20
115	Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding. Protein Engineering, Design and Selection, 1998, 11, 1267-1276.	1.0	33
116	Molecular Characterization of Five Neutralizing Anti-HIV Type 1 Antibodies: Identification of Nonconventional D Segments in the Human Monoclonal Antibodies 2G12 and 2F5. AIDS Research and Human Retroviruses, 1998, 14, 1115-1128.	0.5	103
117	Identification of V3 Loop-binding Proteins as Potential Receptors Implicated in the Binding of HIV Particles to CD4+Cells. Journal of Biological Chemistry, 1998, 273, 21988-21997.	1.6	66
118	Specific Killing of HIV-infected Lymphocytes by a Recombinant Immunotoxin Directed against the HIV-1 Envelope Glycoprotein. Molecular Medicine, 1998, 4, 384-391.	1.9	39
119	Human Antibody Responses to Mature and Immature Forms of Viral Envelope in Respiratory Syncytial Virus Infection: Significance for Subunit Vaccines. Journal of Virology, 1999, 73, 2956-2962.	1.5	52
120	Recombinant Human Monoclonal Antibodies to Ebola Virus. Journal of Infectious Diseases, 1999, 179, S235-S239.	1.9	93
121	Construction of Murine Phage Antibody Library and Selection of Ricin-Specific Single-Chain Antibodies. IUBMB Life, 1999, 48, 513-517.	1.5	3
122	Generation of native bovine mAbs by phage display. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 640-645.	3.3	47
123	A Lewisy epitope mimicking peptide induces anti-Lewisy immune responses in rabbits and mice. Chemical Biology and Drug Design, 1999, 53, 252-260.	1.2	20
124	Possible presence of enhancing antibodies in idiopathic thrombocytopenic purpura. British Journal of Haematology, 1999, 104, 69-80.	1.2	11
125	Natural Human Antibodies Retrieved by Phage Display Libraries from Healthy Donors: Polyreactivity and Recognition of Human Immunodeficiency Virus Type 1 gp120 Epitopes. Scandinavian Journal of Immunology, 1999, 50, 270-279.	1.3	16
126	Construction of Murine Phage Antibody Library and Selection of Ricinâ€Specific Singleâ€Chain Antibodies. IUBMB Life, 1999, 48, 513-517.	1.5	6
127	Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. EMBO Journal, 1999, 18, 6771-6785.	3.5	152
128	Generation of Recombinant Antibodies. Molecular Biotechnology, 1999, 12, 173-202.	1.3	64

#	Article	IF	Citations
129	Construction of human combinatorial antibody library and screening of monoclonal antibody Fabs to human immunodeficiency virus type I. Science Bulletin, 1999, 44, 352-356.	1.7	0
130	Cloning the antibody response in humans with inflammatory CNS disease: isolation of measles virus-specific antibodies from phage display libraries of a subacute sclerosing panencephalitis brain. Journal of Neuroimmunology, 1999, 94, 204-211.	1.1	36
131	Application of a recombinant Fab fragment from a phage display library for sensitive detection of a target antigen by an inhibition ELISA system. Journal of Immunological Methods, 1999, 223, 107-114.	0.6	17
132	Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo. Immunity, 1999, 10, 431-438.	6.6	221
133	A recombinant Fab neutralizes dengue virus in vitro. Journal of Biotechnology, 1999, 69, 183-190.	1.9	46
134	Recombinant Human Monoclonal Fab Fragments against Rotaviras from Phage Display Combinatorial Libraries. Journal of Biochemistry, 1999, 125, 123-129.	0.9	12
135	A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. , 2000, 60, 446-454.		29
136	Natural and designer binding sites made by phage display technology. Trends in Immunology, 2000, 21, 371-378.	7.5	202
137	The use of phage display for the development of tumour targeting agents. Advanced Drug Delivery Reviews, 2000, 43, 165-196.	6.6	101
138	Humanization of a mouse monoclonal antibody neutralizing TNF-Î± by guided selection. Journal of Immunological Methods, 2000, 241, 171-184.	0.6	25
139	Applying phage display technology in aging research. Biogerontology, 2000, 1, 67-78.	2.0	10
140	Tracking Immunoglobulin Variable-Gene Expression in HIV Infection. Applied Biochemistry and Biotechnology, 2000, 83, 13-30.	1.4	3
141	Antibodies in Human Infectious Disease. Immunologic Research, 2000, 21, 265-278.	1.3	11
142	Identification of gp120 Regions Targeted by a Highly Potent Neutralizing Antiserum Elicited in a Chimpanzee Inoculated with a Primary Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology, 2000, 74, 9749-9754.	1.5	30
143	Cloning the Antibody Response in Humans with Chronic Inflammatory Disease: Immunopanning of Subacute Sclerosing Panencephalitis (SSPE) Brain Sections with Antibody Phage Libraries Prepared from SSPE Brain Enriches for Antibody Recognizing Measles Virus Antigens In Situ. Journal of Virology, 2000, 74, 1533-1537.	1.5	18
144	Cloning and expression of a novel human antibody-antigen pair associated with Felty's syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 9234-9239.	3.3	55
145	Antibody-Based Therapies in Infectious Diseases. Methods in Molecular Medicine, 2000, 40, 157-178.	0.8	2
146	A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex. Journal of Virology, 2000, 74, 4183-4191.	1.5	46

#	Article	IF	Citations
147	The Human Anti-bullous Pemphigoid Monoclonal Autoantibody P22 is Encoded by Genes of the IGHV4 and IGLV4 Families. Journal of Autoimmunity, 2000, 15, 459-468.	3.0	4
148	Identification by Phage Display and Characterization of Two Neutralizing Chimpanzee Monoclonal Antibodies to the Hepatitis E Virus Capsid Protein. Journal of Virology, 2000, 74, 5548-5555.	1.5	154
149	Strain-specified relative conformational stability of the scrapie prion protein. Protein Science, 2001, 10, 854-863.	3.1	239
150	GP120: Biologic Aspects of Structural Features. Annual Review of Immunology, 2001, 19, 253-274.	9.5	226
151	Molecular profile of a human monoclonal antibody fab fragment specific for Epstein-Barr virus gp350/220 antigen. Human Immunology, 2001, 62, 362-367.	1.2	6
152	Human therapeutic antibodies. Current Opinion in Pharmacology, 2001, 1, 404-408.	1.7	28
153	Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro. Journal of Virology, 2001, 75, 8340-8347.	1.5	649
154	A novel expression vector for production of epitope-tagged recombinant Fab fragments in bacteria. Human Antibodies, 2001, 10, 149-154.	0.6	3
155	Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins. Current Pharmaceutical Biotechnology, 2001, 2, 19-46.	0.9	17
156	Phage antibodies from combinatorial library neutralize vaccinia virus. Human Antibodies, 2001, 10, 95-99.	0.6	4
157	A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Critical Reviews in Oncology/Hematology, 2001, 40, 25-35.	2.0	50
158	Solid phase synthesis of mixture-based acyclic and heterocyclic small molecule combinatorial libraries from resin-bound polyamides. Biopolymers, 2001, 60, 212-219.	1.2	13
159	External Surface Display of Proteins Linked to DNA-Binding Domains. Analytical Biochemistry, 2001, 294, 108-117.	1.1	5
160	Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs. Virology, 2001, 288, 29-35.	1.1	38
161	Molecular determinants of the human antibody response to HIV-1: implications for disease control. Journal of Clinical Immunology, 2001, 21, 410-419.	2.0	12
162	Use of human CD4 transgenic mice for studying immunogenicity of HIV-1 envelope protein gp120. Transgenic Research, 2001, 10, 113-120.	1.3	4
163	The Rescue by Phage Display of Human Fabs to gp120 HIV-1 Glycoprotein Using EBV Transformed Lymphocytes. Molecular Biotechnology, 2001, 17, 097-108.	1.3	6
164	Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nature Immunology, 2001, 2, 746-753.	7.0	187

#	Article	IF	Citations
165	Phage Display Cloning and Characterization of Monoclonal Antibody Genes and Recombinant Fab Fragment against the CD98 Oncoprotein. Japanese Journal of Cancer Research, 2001, 92, 1313-1321.	1.7	15
166	Research and clinical applications of antibody phage display in transfusion medicine1. Transfusion Medicine Reviews, 2001, 15, 35-52.	0.9	14
167	Biotechnological applications of phage and cell display. Biotechnology Advances, 2001, 19, 1-33.	6.0	212
168	Antibody libraries in drug and target discovery. Drug Discovery Today, 2001, 6, 36-43.	3.2	33
169	The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12659-12664.	3.3	157
170	Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1793-1798.	3.3	100
171	Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells. Antimicrobial Agents and Chemotherapy, 2001, 45, 664-672.	1.4	89
172	Isolation of the Melanoma-Associated Antigen p23 Using Antibody Phage Display. Journal of Immunology, 2001, 166, 432-438.	0.4	22
173	Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 2741-2752.	1.5	55
174	Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12. Journal of Virology, 2001, 75, 6692-6699.	1.5	85
175	Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies. Journal of Virology, 2001, 75, 12198-12208.	1.5	148
176	Postattachment Neutralization of a Primary Strain of HIV Type 1 in Peripheral Blood Mononuclear Cells Is Mediated by CD4-Specific Antibodies But Not by a Glycoprotein 120-Specific Antibody that Gives Potent Standard Neutralization. AIDS Research and Human Retroviruses, 2001, 17, 1645-1654.	0.5	9
177	Isolation and Functional Characterization of Recombinant GAD65 Autoantibodies Derived by IgG Repertoire Cloning From Patients With Type 1 Diabetes. Diabetes, 2001, 50, 1976-1982.	0.3	9
178	Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 12161-12168.	1.5	246
179	Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41. Journal of Virology, 2001, 75, 10892-10905.	1.5	734
180	Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6. Journal of Virology, 2001, 75, 9177-9186.	1.5	46
181	CCR5, CXCR4, and CD4 Are Clustered and Closely Apposed on Microvilli of Human Macrophages and T Cells. Journal of Virology, 2001, 75, 3779-3790.	1.5	149
182	Blocking Immunodominant Epitopes by Competitive Deselection. , 2002, 178, 173-177.		0

#	Article	IF	Citations
183	Rescue of a Broader Range of Antibody Specificities Using an Epitope-Masking Strategy. , 2002, 178, 179-186.		8
184	Development of a Safe and Rapid Neutralization Assay Using Murine Leukemia Virus Pseudotyped with HIV Type 1 Envelope Glycoprotein Lacking the Cytoplasmic Domain. AIDS Research and Human Retroviruses, 2001, 17, 1715-1724.	0.5	26
185	Translocation of an Intracellular Antigen to the Surface of Medullary Breast Cancer Cells Early in Apoptosis Allows for an Antigen-Driven Antibody Response Elicited by Tumor-Infiltrating B Cells. Journal of Immunology, 2002, 169, 2701-2711.	0.4	73
186	Analysis of a Primary Isolate-like Virus from Simian and Human Immunodeficiency Virus-Infected Macaque Having Broad Neutralizing Activity. AIDS Research and Human Retroviruses, 2002, 18, 469-475.	0.5	2
187	Increased Affinity and Stability of an Anti-HIV-1 Envelope Immunotoxin by Structure-based Mutagenesis. Journal of Biological Chemistry, 2002, 277, 34383-34390.	1.6	33
188	Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci. Journal of Immunology, 2002, 169, 595-605.	0.4	61
189	Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology, 2002, 76, 6277-6292.	1.5	211
190	Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer. Journal of Virology, 2002, 76, 8769-8775.	1.5	110
191	Generation of Antibody Molecules Through Antibody Engineering. , 2003, 207, 03-26.		8
192	Neutralizing Human Fab Fragments against Measles Virus Recovered by Phage Display. Journal of Virology, 2002, 76, 251-258.	1.5	36
193	A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response. Journal of Virology, 2002, 76, 644-655.	1.5	84
194	Truncation of the Cytoplasmic Domain Induces Exposure of Conserved Regions in the Ectodomain of Human Immunodeficiency Virus Type 1 Envelope Protein. Journal of Virology, 2002, 76, 2683-2691.	1.5	163
195	Solution Structure of a Putative HIV1 Immunogenic Peptide:â€‰ Computer Simulation of the Principal CD4 Binding Domain of gp120. Journal of Medicinal Chemistry, 2002, 45, 1019-1025.	2.9	5
196	Tailoring Kinetics of Antibodies Using Focused Combinatorial Libraries. , 2003, 207, 213-234.		4
197	Herpesvirus saimiri-Immortalized Human Lymphocytes: Novel Hosts for Analyzing HIV Type 1in VitroNeutralization. AIDS Research and Human Retroviruses, 2002, 18, 933-946.	0.5	5
198	A Change in the Conformation of Prions Accompanies the Emergence of a New Prion Strain. Neuron, 2002, 34, 921-932.	3.8	214
200	Protein microarray technology. Frontiers in Bioscience - Landmark, 2002, 7, c13-32.	3.0	3
201	Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library. Journal of Immunological Methods, 2002, 261, 37-48.	0.6	7

#	Article	IF	Citations
203	Coiled coil miniprotein randomization on phage leads to charge pattern mimicry of the receptor recognition determinant of interleukin 5. Journal of Molecular Recognition, 2002, 15, 33-43.	1.1	5
204	Evolution of antibodies for environmental monitoring: from mice to plants. Analytica Chimica Acta, 2002, 468, 185-197.	2.6	12
205	Back to the Future: Antibody-Based Strategies for the Treatment of Infectious Diseases. Molecular Biotechnology, 2002, 21, 225-240.	1.3	14
206	Immunogenicity and Ability of Variable Loop-Deleted Human Immunodeficiency Virus Type 1 Envelope Glycoproteins to Elicit Neutralizing Antibodies. Virology, 2003, 305, 124-137.	1.1	57
207	Emerging trends in the synthesis and improvement of hapten-specific recombinant antibodies. Biotechnology Advances, 2003, 21, 599-637.	6.0	57
208	Two expression vectors for the phage-displayed chicken monoclonal antibody. Journal of Immunological Methods, 2003, 280, 157-164.	0.6	18
209	Paratope-based protein identification by antibody and peptide phage display. Analytical Biochemistry, 2003, 321, 96-104.	1.1	6
210	The role of somatic mutation in determining the affinity of anti-DNA antibodies. Clinical and Experimental Immunology, 2003, 131, 182-189.	1.1	18
211	PCR Cloning of Human Immunoglobulin Genes. , 2004, 248, 117-134.		14
212	New technologies in therapeutic antibody development. Current Opinion in Pharmacology, 2003, 3, 544-550.	1.7	63
213	Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2â€²F-RNA Aptamers. Journal of Virology, 2003, 77, 12692-12698.	1.5	167
214	Production and Characterization of a Human Recombinant Monoclonal Fab Fragment Specific for Influenza A Viruses. Vaccine Journal, 2003, 10, 680-685.	3.2	12
215	Multiple Interactions across the Surface of the gp120 Core Structure Determine the Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1. Journal of Virology, 2003, 77, 8061-8071.	1.5	18
216	Dissecting the Cellular Functions of Annexin XI Using Recombinant Human Annexin XI-specific Autoantibodies Cloned by Phage Display. Journal of Biological Chemistry, 2003, 278, 33120-33126.	1.6	26
217	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2003, 77, 642-658.	1.5	237
218	Envelope Variants from Women Recently Infected with Clade A Human Immunodeficiency Virus Type 1 Confer Distinct Phenotypes That Are Discerned by Competition and Neutralization Experiments. Journal of Virology, 2003, 77, 8448-8461.	1.5	8
219	Molecular Structural and Functional Characterization of Tumor Suppressive Anti-ErbB-2 Monoclonal Antibody by Phage Display System. Journal of Biochemistry, 2003, 133, 239-245.	0.9	11
220	Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design. Journal of Virology, 2003, 77, 5889-5901.	1.5	126

#	Article	IF	Citations
221	Modern Methods of Drug Discovery. , 2003, , .		17
222	Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2003, 77, 5863-5876.	1.5	100
223	CD4-dependent and CD4-independent HIV-2. Aids, 2003, 17, 291-300.	1.0	37
224	Mixture-Based Combinatorial Libraries: From Peptides and Peptidomimetics to Small Molecule Acyclic and Heterocyclic Compounds. Methods in Enzymology, 2003, 369, 496-517.	0.4	14
225	Immunoassay of infectious agents. BioTechniques, 2003, 35, 850-859.	0.8	121
226	Human Monoclonal Antibody Fragment Specific for Glycoprotein G in Herpes Simplex Virus Type 2 with Applications for Serotype-Specific Diagnosis. Journal of Clinical Microbiology, 2004, 42, 1250-1253.	1.8	9
227	Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody. Journal of Virology, 2004, 78, 9233-9242.	1.5	80
228	Specificity Rescue and Affinity Maturation of a Low-Affinity IgM Antibody against Pro-Gastrin-Releasing Peptide using Phage Display and DNA Shuffling. Tumor Biology, 2004, 25, 7-13.	0.8	12
229	Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Engineering, Design and Selection, 2004, 17, 749-758.	1.0	54
230	Isolation of foot-and-mouth disease virus specific bovine antibody fragments from phage display libraries. Journal of Immunological Methods, 2004, 286, 155-166.	0.6	5
231	Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display. Virology, 2004, 318, 598-607.	1.1	27
232	Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology, 2004, 321, 75-86.	1.1	30
233	A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Virology, 2004, 326, 299-309.	1.1	13
234	Generation and Production of Engineered Antibodies. Molecular Biotechnology, 2004, 26, 39-60.	1.3	57
235	Transgenic tobacco cells producing the human monoclonal antibody to hepatitis B virus surface antigen. Journal of Medical Virology, 2004, 73, 208-215.	2.5	54
236	Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. Journal of Virology, 2004, 78, 13232-13252.	1.5	665
237	Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Review of Vaccines, 2004, 3, S53-S64.	2.0	22
238	Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection. Vaccine, 2004, 22, 383-397.	1.7	2

#	Article	IF	Citations
239	Molecular Analysis of the Human Autoantibody Response to Î±-Fodrin in SjÃ¶gren's Syndrome Reveals Novel Apoptosis-Induced Specificity. American Journal of Pathology, 2004, 165, 53-61.	1.9	31
240	Inhibition of Hepatitis C Virus Nonstructural Protein, Helicase Activity, and Viral Replication by a Recombinant Human Antibody Clone. American Journal of Pathology, 2004, 165, 1163-1173.	1.9	24
241	Detection of biological threats. A challenge for directed molecular evolution. Journal of Microbiological Methods, 2004, 58, 147-168.	0.7	101
242	HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. Aids, 2004, 18, 1769-1779.	1.0	57
243	Characterization of a Shiga Toxin 1-Neutralizing Recombinant Fab Fragment Isolated by Phage Display System. Tohoku Journal of Experimental Medicine, 2004, 203, 295-303.	0.5	10
244	Selecting and screening recombinant antibody libraries. Nature Biotechnology, 2005, 23, 1105-1116.	9.4	883
245	Molecular characterization of the circulating anti-HIV-1 gp120-specific B cell repertoire using antibody phage display libraries generated from pre-selected HIV-1 gp120 binding PBLs. Journal of Immunological Methods, 2005, 297, 187-201.	0.6	13
246	Construction, evaluation and refinement of a large human antibody phage library based on the IgD and IgM variable gene repertoire. Journal of Immunological Methods, 2005, 299, 47-62.	0.6	56
247	Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology, 2005, 331, 20-32.	1.1	54
248	Infection of human and non-human cells by a highly fusogenic primary CD4-independent HIV-1 isolate with a truncated envelope cytoplasmic tail. Virology, 2005, 337, 30-44.	1.1	13
249	Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology, 2005, 337, 384-398.	1.1	108
250	HCV-hepatocellular carcinoma: New findings and hope for effective treatment. Microscopy Research and Technique, 2005, 68, 130-148.	1.2	13
251	The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Analytical Biochemistry, 2005, 336, 145-157.	1.1	110
252	Concepts for the Development of Immunodiagnostic Assays for Detection and Diagnosis of Biothreat Agents. , 2005, , 551-579.		0
253	A Highly Conserved Arginine in gp120 Governs HIV-1 Binding to Both Syndecans and CCR5 via Sulfated Motifs. Journal of Biological Chemistry, 2005, 280, 39493-39504.	1.6	73
254	The Cytoplasmic Tail Slows the Folding of Human Immunodeficiency Virus Type 1 Env from a Late Prebundle Configuration into the Six-Helix Bundle. Journal of Virology, 2005, 79, 106-115.	1.5	81
255	Comparing Antigenicity and Immunogenicity of Engineered gp120. Journal of Virology, 2005, 79, 12148-12163.	1.5	96
256	Isolating human antibody against human hepatocellular carcinoma by guided-selection. Cancer Biology and Therapy, 2005, 4, 1374-1380.	1.5	14

#	Article	IF	Citations
257	Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opinion on Investigational Drugs, 2005, 14, 1199-1212.	1.9	26
258	Immunogenicity of HIV Type 1 gp120 CD4 Binding Site Phage Mimotopes. AIDS Research and Human Retroviruses, 2005, 21, 82-92.	0.5	31
259	A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Engineering, Design and Selection, 2006, 19, 461-470.	1.0	27
260	Construction and characterization of a pseudo-immune human antibody library using yeast surface display. Biochemical and Biophysical Research Communications, 2006, 346, 896-903.	1.0	28
261	Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs. Journal of Molecular Biology, 2006, 357, 82-99.	2.0	21
262	Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. Molecular Immunology, 2006, 43, 1363-1369.	1.0	4
263	Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide. Vaccine, 2006, 24, 4188-4200.	1.7	65
264	HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine, 2006, 24, 5442-5451.	1.7	18
266	Making Antibodies in Bacteria. , 2006, , 157-180.		18
267	Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified antiâ€“HIV-1 IgG without induction of maturation. Blood, 2006, 107, 4466-4474.	0.6	59
268	Miniaturized Multiplexed Protein Binding Assays. , 2006, , 61-87.		0
270	Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnology and Applied Biochemistry, 2006, 45, 93.	1.4	26
271	Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. Journal of Immunological Methods, 2006, 317, 21-30.	0.6	32
272	Manufacturing Immunity to Disease in a Test Tube: The Magic Bullet Realized. Angewandte Chemie - International Edition, 2006, 45, 8106-8125.	7.2	71
274	Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold. Protein Engineering, Design and Selection, 2006, 19, 231-244.	1.0	20
275	Antibodies and their Fragments as Anti-Cancer Agents. Current Pharmaceutical Design, 2006, 12, 363-378.	0.9	35
276	Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant. Journal of Virology, 2006, 80, 835-844.	1.5	271
277	Computational prediction of the crossâ€reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIVâ€1 gp120. FASEB Journal, 2006, 20, 1762-1774.	0.2	34

#	Article	IF	Citations
278	An Immunoglobulin Fusion Protein Based on the gp120-CD4 Receptor Complex Potently Inhibits Human Immunodeficiency Virus Type 1in Vitro. AIDS Research and Human Retroviruses, 2006, 22, 477-490.	0.5	11
279	Phage escape libraries for checkmate analysis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12703-12708.	3.3	4
280	Novel Approaches for Identification of Broadly Cross-Reactive HIV-1 Neutralizing Human Monoclonal Antibodies and Improvement of Their Potency. Current Pharmaceutical Design, 2007, 13, 203-212.	0.9	23
281	Production and Characterization of High-Affinity Human Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in a Mouse Model Expressing Human Immunoglobulins. Vaccine Journal, 2007, 14, 157-167.	3.2	5
282	HIV-1 rational vaccine design: molecular details of b12â€“gp120 complex structure. Expert Review of Vaccines, 2007, 6, 319-321.	2.0	4
283	Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses. Journal of Virology, 2007, 81, 13037-13049.	1.5	21
284	Generation of Human Monoclonal Allergen-Specific IgE and IgG Antibodies from Synthetic Antibody Libraries. Clinical Chemistry, 2007, 53, 837-844.	1.5	26
285	Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. Journal of Virology, 2007, 81, 6548-6562.	1.5	181
286	Direct Inactivation of Human Immunodeficiency Virus Type 1 by a Novel Small-Molecule Entry Inhibitor, DCM205. Antimicrobial Agents and Chemotherapy, 2007, 51, 1780-1786.	1.4	8
287	Peptides Selected from a Phage Display Library with an HIV-Neutralizing Antibody Elicit Antibodies to HIV gp120 in Rabbits, But Not to the Same Epitope. AIDS Research and Human Retroviruses, 2007, 23, 1416-1427.	0.5	11
288	Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology, 2007, 4, 89.	0.9	82
289	Design of synthetic antibody libraries. Expert Opinion on Biological Therapy, 2007, 7, 763-779.	1.4	51
290	The growth and potential of human antiviral monoclonal antibody therapeutics. Nature Biotechnology, 2007, 25, 1421-1434.	9.4	256
291	An hepatitis B virus surface antigen specific single chain of variable fragment derived from a natural immune antigen binding fragment phage display library is specifically internalized by HepG2.2.15 cells. Journal of Viral Hepatitis, 2007, 14, 512-519.	1.0	13
292	Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients. Antiviral Research, 2007, 75, 129-138.	1.9	4
293	Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Î”32 heterozygote. Virology, 2007, 362, 163-178.	1.1	42
294	Selection and characterization of scFv antibodies against the Sin Nombre hantavirus nucleocapsid protein. Journal of Immunological Methods, 2007, 321, 60-69.	0.6	30
295	Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunology, Immunotherapy, 2007, 56, 677-687.	2.0	58

#	Article	IF	Citations
296	Generation of genetic engineering monoclonal antibodies against prion protein. Medical Microbiology and Immunology, 2007, 196, 241-246.	2.6	2
297	Translational applications of antibody phage display. Immunologic Research, 2008, 42, 118-131.	1.3	18
298	Identification of a human heavy chain antibody fragment directed against human platelet alloantigen la by phage display library. Tissue Antigens, 1998, 51, 156-163.	1.0	11
299	Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology, 2008, 370, 246-254.	1.1	37
300	N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology, 2008, 372, 187-200.	1.1	36
301	An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology, 2008, 381, 46-54.	1.1	52
302	Isolation of Human Antiâ€Red Blood Cell Antibodies by Repertoire Cloning^a. Annals of the New York Academy of Sciences, 1995, 764, 547-558.	1.8	8
303	Recombinant Antibodies as Therapeutic Agents. BioDrugs, 2008, 22, 301-314.	2.2	57
304	Focused Dampening of Antibody Response to the Immunodominant Variable Loops by Engineered Soluble gp140. AIDS Research and Human Retroviruses, 2008, 24, 301-314.	0.5	36
305	Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120. Journal of Virology, 2008, 82, 12069-12081.	1.5	103
306	A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. Journal of Virology, 2008, 82, 6359-6368.	1.5	112
307	Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. Journal of Virology, 2008, 82, 638-651.	1.5	154
308	Construction of Recombinant Mouse IgG1 Antibody Directed Against Varicella Zoster Virus Immediate Early Protein 63. Hybridoma, 2008, 27, 1-10.	0.5	5
309	A recombinant human monoclonal anti-R7V antibody as a potential therapy for HIV infected patients in failure of HAART. Human Antibodies, 2008, 16, 73-85.	0.6	1
310	Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques. Journal of Immunology, 2009, 183, 2537-2544.	0.4	27
311	Autoantibodies against C1q in Systemic Lupus Erythematosus Are Antigen-Driven. Journal of Immunology, 2009, 183, 8225-8231.	0.4	50
312	Phosphorylation of the Nuclear Form of Varicella-Zoster Virus Immediate-Early Protein 63 by Casein Kinase II at Serine 186. Journal of Virology, 2009, 83, 12094-12100.	1.5	9
313	Antibody-Mediated Fcî³ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies. Viruses, 2009, 1, 1265-1294.	1.5	25

#	Article	IF	Citations
314	Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. Journal of Virology, 2009, 83, 7337-7348.	1.5	538
315	A method for identification of HIV gp140 binding memory B cells in human blood. Journal of Immunological Methods, 2009, 343, 65-67.	0.6	204
316	Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology, 2009, 385, 275-281.	1.1	34
317	Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology, 2009, 389, 108-121.	1.1	50
318	Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology, 2009, 395, 33-44.	1.1	20
319	Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnology Advances, 2009, 27, 502-520.	6.0	214
320	Crystal structure of a 3B3 variantâ€"A broadly neutralizing HIVâ€1 scFv antibody. Protein Science, 2009, 18, 2429-2441.	3.1	16
321	Specific Fab fragments recovered by phage display technique recognizing human spermatozoa. Journal of Developmental and Physical Disabilities, 2009, 32, 442-452.	3.6	5
322	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 2009, 458, 636-640.	13.7	806
323	Design of a Human Synthetic Combinatorial Library of Single-Chain Antibodies. Methods in Molecular Biology, 2009, 525, 61-80.	0.4	15
324	Overview on Concepts and Applications of Fab Antibody Fragments. Current Protocols in Protein Science, 2009, 55, Unit 6.9.	2.8	21
325	Therapeutic Antibodies. Methods in Molecular Biology, 2009, 525, vii-viii, xiii.	0.4	9
326	Isolation of Monoclonal Antibody Fragments from Phage Display Libraries. Methods in Molecular Biology, 2009, 502, 341-364.	0.4	28
327	Bacteriophages. Methods in Molecular Biology, 2009, , .	0.4	35
328	An Internalizing Antibody Specific for the Human Asialoglycoprotein Receptor. Hybridoma, 2009, 28, 225-233.	0.5	8
329	Alternative Scaffolds: Expanding the Options of Antibodies. , 2009, , 243-272.		4
330	Antibodies from IgM Libraries. , 0, , 66-74.		3
331	Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA. Journal of Immunotherapy, 2009, 32, 341-352.	1.2	69

#	Article	IF	Citations
332	Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. Virology, 2010, 400, 164-174.	1.1	41
333	Biomarker discovery and clinical proteomics. TrAC - Trends in Analytical Chemistry, 2010, 29, 128-140.	5.8	78
334	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.	13.7	393
336	A Strategy for Eliciting Antibodies against Cryptic, Conserved, Conformationally Dependent Epitopes of HIV Envelope Glycoprotein. PLoS ONE, 2010, 5, e8555.	1.1	13
337	Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE, 2010, 5, e8805.	1.1	405
338	Two N-Linked Glycosylation Sites in the V2 and C2 Regions of Human Immunodeficiency Virus Type 1 CRF01_AE Envelope Glycoprotein gp120 Regulate Viral Neutralization Susceptibility to the Human Monoclonal Antibody Specific for the CD4 Binding Domain. Journal of Virology, 2010, 84, 4311-4320.	1.5	35
339	IgG Subclass Profiles in Infected HIV Type 1 Controllers and Chronic Progressors and in Uninfected Recipients of Env Vaccines. AIDS Research and Human Retroviruses, 2010, 26, 445-458.	0.5	107
340	Human antiâ€“HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. Journal of Experimental Medicine, 2010, 207, 1995-2002.	4.2	62
341	The First Human Epitope Map of the Alphaviral E1 and E2 Proteins Reveals a New E2 Epitope with Significant Virus Neutralizing Activity. PLoS Neglected Tropical Diseases, 2010, 4, e739.	1.3	47
342	Accessing the human repertoire for broadly neutralizing HIV antibodies. MAbs, 2010, 2, 157-164.	2.6	24
343	Mining human antibody repertoires. MAbs, 2010, 2, 365-378.	2.6	47
344	The Use of Phage Display in Neurobiology. Current Protocols in Neuroscience, 2010, 51, Unit 5.12.	2.6	10
345	Remodeling of Dynamic Structures of HIV-1 Envelope Proteins Leads to Synthetic Antigen Molecules Inducing Neutralizing Antibodies. Bioconjugate Chemistry, 2010, 21, 709-714.	1.8	19
346	Toward an Antibody-Based HIV-1 Vaccine. Annual Review of Medicine, 2010, 61, 135-152.	5.0	110
347	Global structure of HIV-1 neutralizing antibody IgG1 b12 is asymmetric. Biochemical and Biophysical Research Communications, 2010, 391, 947-951.	1.0	20
348	Therapeutic antibodies, vaccines and antibodyomes. MAbs, 2010, 2, 347-356.	2.6	129
349	Phage Display Technology in Biosensor Development. , 2010, , 723-749.		0
350	Production of Antibody Fab Fragments in Escherichia coli. Cell Engineering, 2011, , 165-178.	0.4	0

#	Article	IF	Citations
351	Antibody Expression and Production. Cell Engineering, 2011, , .	0.4	4
352	HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine, 2011, 29, 4913-4922.	1.7	23
353	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science, 2011, 333, 1633-1637.	6.0	1,046
355	Longitudinal Study of Primary HIV-1 Isolates in Drug-NaÃ¯ve Individuals Reveals the Emergence of Variants Sensitive to Anti-HIV-1 Monoclonal Antibodies. PLoS ONE, 2011, 6, e17253.	1.1	5
356	Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge. PLoS ONE, 2011, 6, e20135.	1.1	16
357	Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses. PLoS ONE, 2011, 6, e24078.	1.1	99
358	High Affinity, Developability and Functional Size: The Holy Grail of Combinatorial Antibody Library Generation. Molecules, 2011, 16, 3675-3700.	1.7	127
359	Generation and epitope analysis of human monoclonal antibody isotypes with specificity for the timothy grass major allergen Phl p 5a. Molecular Immunology, 2011, 48, 1236-1244.	1.0	17
360	NanobodiesÂ®: New ammunition to battle viruses. Antiviral Research, 2011, 92, 389-407.	1.9	123
361	Antibody-mediated resistance against plant pathogens. Biotechnology Advances, 2011, 29, 961-971.	6.0	46
362	Generation of Human Fab Antibody Libraries: PCR Amplification and Assembly of Light- and Heavy-Chain Coding Sequences. Cold Spring Harbor Protocols, 2011, 2011, pdb.prot065565.	0.2	12
363	Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Retrovirology, 2011, 8, 37.	0.9	45
364	Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virology Journal, 2011, 8, 429.	1.4	7
365	HIV sexual transmission and microbicides. Reviews in Medical Virology, 2011, 21, 110-133.	3.9	47
366	Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminumâ€containing adjuvants on the immune response. Journal of Pharmaceutical Sciences, 2011, 100, 3245-3250.	1.6	28
367	Restricted occupancy models for neutralization of HIV virions and populations. Journal of Theoretical Biology, 2011, 283, 192-202.	0.8	20
368	Broadening horizons of antibody engineering. Protein Engineering, Design and Selection, 2011, 24, 631-632.	1.0	1
369	Construction and Phenotypic Characterization of HIV Type 1 Functional Envelope Clones of Subtypes G and F. AIDS Research and Human Retroviruses, 2011, 27, 889-901.	0.5	19

#	Article	IF	Citations
370	Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins. Journal of Virology, 2011, 85, 8514-8527.	1.5	110
371	Designed oligomers of cyanovirin-N show enhanced HIV neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14079-14084.	3.3	38
372	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology, 2011, 85, 5804-5813.	1.5	37
373	Microarray technology displays the complexities of the humoral immune response. Expert Review of Molecular Diagnostics, 2011, 11, 5-8.	1.5	8
374	Cross-reactive broadly neutralizing antibodies: timing is everything. Frontiers in Immunology, 2012, 3, 215.	2.2	27
375	Phages and HIV-1: From Display to Interplay. International Journal of Molecular Sciences, 2012, 13, 4727-4794.	1.8	17
376	Enhanced HIV-1 neutralization by antibody heteroligation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 875-880.	3.3	52
377	Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. Journal of Experimental Medicine, 2012, 209, 1091-1103.	4.2	91
378	High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2012, 86, 2153-2164.	1.5	57
379	HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug. Antimicrobial Agents and Chemotherapy, 2012, 56, 4257-4267.	1.4	30
380	Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood, 2012, 120, 4571-4582.	0.6	74
381	Transferring the Characteristics of Naturally Occurring and Biased Antibody Repertoires to Human Antibody Libraries by Trapping CDRH3 Sequences. PLoS ONE, 2012, 7, e43471.	1.1	22
382	Synthetic antibodies: Concepts, potential and practical considerations. Methods, 2012, 57, 486-498.	1.9	97
383	The use of phage display to generate conformation-sensor recombinant antibodies. Nature Protocols, 2012, 7, 2127-2143.	5.5	32
384	Germline VH/VL pairing in antibodies. Protein Engineering, Design and Selection, 2012, 25, 523-530.	1.0	50
385	Two Synthetic Antibodies that Recognize and Neutralize Distinct Proteolytic Forms of the Ebola Virus Envelope Glycoprotein. ChemBioChem, 2012, 13, 2549-2557.	1.3	26
386	Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12. Virology, 2012, 432, 394-404.	1.1	1
387	Selection of antibodies from synthetic antibody libraries. Archives of Biochemistry and Biophysics, 2012, 526, 87-98.	1.4	23

#	Article	IF	Citations
388	Development of recombinant single-chain variable fragment against hepatitis A virus and its use in quantification of hepatitis A antigen. Biologicals, 2012, 40, 299-308.	0.5	5
389	Technologies for the Generation of Human Antibodies. , 2012, , 33-63.		1
390	Phage Display-based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed against Human Pathogens. International Journal of Molecular Sciences, 2012, 13, 8273-8292.	1.8	37
391	Candidate Antibody-Based Therapeutics Against HIV-1. BioDrugs, 2012, 26, 143-162.	2.2	13
393	Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes. PLoS ONE, 2012, 7, e36750.	1.1	113
394	Accessing of recombinant human monoclonal antibodies from patient libraries by eukaryotic ribosome display. Human Antibodies, 2012, 21, 1-11.	0.6	8
395	Recombinant Antibodies and In Vitro Selection Technologies. Methods in Molecular Biology, 2012, 901, 11-32.	0.4	59
396	Evaluation of a synthetic C34 trimer of HIV-1 gp41 as AIDS vaccines. Bioorganic and Medicinal Chemistry, 2012, 20, 3287-3291.	1.4	14
397	Conformationâ€specific Display of 4E10 and 2F5 Epitopes on Selfâ€assembling Protein Nanoparticles as a Potential HIV Vaccine. Chemical Biology and Drug Design, 2012, 80, 349-357.	1.5	82
398	Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development. , 2013, , 3-33.		10
399	Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. Retrovirology, 2013, 10, 147.	0.9	4
400	Rapid Conformational Epitope Mapping of Anti-gp120 Antibodies with a Designed Mutant Panel Displayed on Yeast. Journal of Molecular Biology, 2013, 425, 444-456.	2.0	56
401	F(abâ€²)2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. Microbes and Infection, 2013, 15, 887-894.	1.0	4
402	Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expression and Purification, 2013, 90, 34-39.	0.6	11
403	Broadly Neutralizing Antiviral Antibodies. Annual Review of Immunology, 2013, 31, 705-742.	9.5	447
404	Insights into B cells and <scp>HIV</scp>â€specific Bâ€cell responses in <scp>HIV</scp>â€infected individuals. Immunological Reviews, 2013, 254, 207-224.	2.8	130
405	Anti-Idiotypic Monobodies Derived from a Fibronectin Scaffold. Biochemistry, 2013, 52, 1802-1813.	1.2	10
406	Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10. PLoS Pathogens, 2013, 9, e1003639.	2.1	44

#	Article	IF	Citations
407	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathogens, 2013, 9, e1003738.	2.1	190
408	The Griffithsin Dimer Is Required for High-Potency Inhibition of HIV-1: Evidence for Manipulation of the Structure of gp120 as Part of the Griffithsin Dimer Mechanism. Antimicrobial Agents and Chemotherapy, 2013, 57, 3976-3989.	1.4	40
409	Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. Journal of Leukocyte Biology, 2013, 93, 113-126.	1.5	36
410	Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120. Journal of Virology, 2013, 87, 10855-10873.	1.5	29
411	Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies. MAbs, 2013, 5, 690-698.	2.6	10
412	B Cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates. Journal of Immunology, 2013, 191, 3179-3185.	0.4	41
413	Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. Virologica Sinica, 2014, 29, 299-307.	1.2	5
414	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17624-17629.	3.3	324
415	A Novel VHH Antibody Targeting the B Cell-Activating Factor for B-Cell Lymphoma. International Journal of Molecular Sciences, 2014, 15, 9481-9496.	1.8	7
416	Pioneering Engineered Antibodies and Immunotherapeutics: Dedicated to Professor James D. Marks. Protein Engineering, Design and Selection, 2014, 27, 297-300.	1.0	1
417	Generation of â€œLYmph Node Derived Antibody Librariesâ€•(LYNDAL) for selecting fully human antibody fragments with therapeutic potential. MAbs, 2014, 6, 130-142.	2.6	9
418	Human I g E against the major allergen B et v 1 â€“ defining an epitope with limited crossâ€•reactivity between different PR â€10 family proteins. Clinical and Experimental Allergy, 2014, 44, 288-299.	1.4	21
419	The Human IgE Repertoire. International Archives of Allergy and Immunology, 2014, 163, 77-91.	0.9	33
420	Profiling the IgOme: Meeting the challenge. FEBS Letters, 2014, 588, 318-325.	1.3	14
421	Synthetic antibody technologies. Current Opinion in Structural Biology, 2014, 24, 1-9.	2.6	57
422	Characterization of human immunodeficiency virus type 1 CRF01_AE env genes derived from recently infected Thai individuals. Microbes and Infection, 2014, 16, 142-152.	1.0	2
423	Genetic methods of antibody generation and their use in immunohistochemistry. Methods, 2014, 70, 20-27.	1.9	8
424	Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies. Journal of Virology, 2014, 88, 13910-13917.	1.5	42

#	Article	IF	Citations
425	Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope. Journal of Virology, 2014, 88, 12853-12865.	1.5	53
426	Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. Virology, 2014, 462-463, 363-376.	1.1	19
427	Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. AIDS Research and Therapy, 2014, 11, 23.	0.7	29
428	Antibody B cell responses in HIV-1 infection. Trends in Immunology, 2014, 35, 549-561.	2.9	91
429	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. Retrovirology, 2014, 11, 32.	0.9	9
430	Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Retrovirology, 2014, 11, 42.	0.9	20
431	Mapping Intracellular Protein Networks. , 2015, , 246-265.		0
432	Mapping Protein Functional Epitopes. , 2015, , 328-341.		0
433	Phage and Yeast Display. Microbiology Spectrum, 2015, 3, AID-0028-2014.	1.2	51
434	Characterization of protective immune response elicited by a trimeric envelope protein from an Indian clade C <scp>HIV</scp>â€1 isolate in rhesus macaques. Journal of Medical Primatology, 2015, 44, 275-285.	0.3	4
435	Vpr Promotes Macrophage-Dependent HIV-1 Infection of CD4+ T Lymphocytes. PLoS Pathogens, 2015, 11, e1005054.	2.1	28
436	The analysis of clonal expansions in normal and autoimmune B cell repertoires. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140239.	1.8	109
437	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature Communications, 2015, 6, 6144.	5.8	130
438	Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies. Cell, 2015, 160, 785-797.	13.5	173
439	Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 2015, 475, 187-203.	1.1	22
440	Identification of optimal protein binders through the use of large genetically encoded display libraries. Current Opinion in Chemical Biology, 2015, 26, 16-24.	2.8	28
441	Bone Marrow Plasma Cells Are a Primary Source of Serum HIV-1â€“Specific Antibodies in Chronically Infected Individuals. Journal of Immunology, 2015, 194, 2561-2568.	0.4	13
442	Structural basis of cladeâ€specific HIVâ€1 neutralization by humanized antiâ€V3 monoclonal antibody KDâ€247. FASEB Journal, 2015, 29, 70-80.	0.2	2

#	Article	IF	Citations
443	CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. Journal of General Virology, 2015, 96, 1899-1905.	1.3	10
444	Antigenic Properties of the Human Immunodeficiency Virus Envelope Glycoprotein Gp120 on Virions Bound to Target Cells. PLoS Pathogens, 2015, 11, e1004772.	2.1	43
445	Antigenicity and Immunogenicity of a Trimeric Envelope Protein from an Indian Clade C HIV-1 Isolate. Journal of Biological Chemistry, 2015, 290, 9195-9208.	1.6	11
446	Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal of Virology, 2015, 89, 11294-11311.	1.5	54
447	Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Therapeutic Delivery, 2015, 6, 795-826.	1.2	91
448	Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region. Virology, 2015, 486, 187-197.	1.1	6
449	Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Critical Reviews in Biotechnology, 2016, 36, 276-289.	5.1	88
451	<scp>V_H</scp> and <scp>V_L</scp> Domains of Polyspecific IgM and Monospecific IgG Antibodies Contribute Differentially to Antigen Recognition and Virus Neutralization Functions. Scandinavian Journal of Immunology, 2016, 84, 28-38.	1.3	7
452	Multimerized HIVâ€gp41â€derived peptides as fusion inhibitors and vaccines. Biopolymers, 2016, 106, 622-628.	1.2	3
454	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. Biochemistry, 2016, 55, 2197-2213.	1.2	23
455	Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits. Vaccine, 2016, 34, 2444-2452.	1.7	3
456	Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. Journal of Experimental Medicine, 2016, 213, 469-481.	4.2	299
457	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. Journal of Virology, 2016, 90, 6127-6139.	1.5	117
458	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. Journal of Virology, 2016, 90, 9224-9236.	1.5	25
459	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16068.	1.8	48
460	Phage display-derived human antibodies in clinical development and therapy. MAbs, 2016, 8, 1177-1194.	2.6	263
461	Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. Journal of Virology, 2016, 90, 4481-4493.	1.5	13
462	Design and construction of a new human naÃ¯ve single-chain fragment variable antibody library, IORISS1. Journal of Biotechnology, 2016, 224, 1-11.	1.9	8

#	Article	IF	Citations
463	Use of computational and recombinant technologies for developing novel influenza vaccines. Expert Review of Vaccines, 2016, 15, 41-51.	2.0	5
464	Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. Journal of Virology, 2016, 90, 829-841.	1.5	21
465	Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal Immunology, 2017, 10, 228-237.	2.7	34
466	Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures. Retrovirology, 2017, 14, 6.	0.9	10
467	Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. Scientific Reports, 2017, 7, 45163.	1.6	18
468	Design and Characterization of a Human Monoclonal Antibody that Modulates Mutant Connexin 26 Hemichannels Implicated in Deafness and Skin Disorders. Frontiers in Molecular Neuroscience, 2017, 10, 298.	1.4	31
469	Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Retrovirology, 2017, 14, 44.	0.9	10
470	Monoclonal Antibodies and Antibody Like Fragments Derived from Immunised Phage Display Libraries. Advances in Experimental Medicine and Biology, 2017, 1053, 99-117.	0.8	6
471	From Biology to Biotechnology: Disulfide Bond Formation in Escherichia coli. , 2017, , .		3
472	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. Nature Communications, 2018, 9, 877.	5.8	65
473	Mid-size Drugs Based on Peptides and Peptidomimetics. SpringerBriefs in Pharmaceutical Science & Drug Development, 2018, , .	0.4	6
474	Peptidomimetics That Mimic the Tertiary Structures of Peptides. SpringerBriefs in Pharmaceutical Science & Drug Development, 2018, , 71-78.	0.4	0
475	Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4. Journal of Biochemistry, 2018, 163, 61-68.	0.9	2
476	Integrating highâ€throughput screening and sequencing for monoclonal antibody discovery and engineering. Immunology, 2018, 153, 31-41.	2.0	72
477	Antibody Isolation From a Human Synthetic Combinatorial and Other Libraries of Single-Chain Antibodies. Methods in Molecular Biology, 2018, 1701, 349-363.	0.4	3
478	Monoclonal antibodies: technologies for early discovery and engineering. Critical Reviews in Biotechnology, 2018, 38, 394-408.	5.1	61
479	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLoS ONE, 2018, 13, e0194266.	1.1	14
480	Antibody-mediated prevention and treatment of HIV-1 infection. Retrovirology, 2018, 15, 73.	0.9	53

#	Article	IF	Citations
481	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host and Microbe, 2018, 24, 579-592.e4.	5.1	88
482	Monoclonal Antibody Generation by Phage Display. , 2018, , 47-80.		6
483	HIV cure: global overview of bNAbsâ€™ patents and related scientific publications. Expert Opinion on Therapeutic Patents, 2018, 28, 551-560.	2.4	2
484	Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. PLoS Pathogens, 2018, 14, e1006986.	2.1	28
485	DEER Spectroscopy Measurements Reveal Multiple Conformations of HIV-1 SOSIP Envelopes that Show Similarities with Envelopes on Native Virions. Immunity, 2018, 49, 235-246.e4.	6.6	68
486	Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?. Journal of Pathogens, 2018, 2018, 1-9.	0.9	20
487	Single molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation. Nature Communications, 2018, 9, 1861.	5.8	35
488	Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype Bâ€² env molecular clones derived from infections in China. Emerging Microbes and Infections, 2018, 7, 1-13.	3.0	4
489	Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies. AIDS Research and Human Retroviruses, 2018, 34, 794-803.	0.5	19
490	Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations. PLoS Pathogens, 2018, 14, e1006812.	2.1	20
491	Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes. Antibodies, 2019, 8, 38.	1.2	25
492	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. Journal of Experimental Medicine, 2019, 216, 2331-2347.	4.2	13
493	Concomitant Enhancement of HIV-1 Replication Potential and Neutralization-Resistance in Concert With Three Adaptive Mutations in Env V1/C2/C4 Domains. Frontiers in Microbiology, 2019, 10, 2.	1.5	8
494	Cognizance of Molecular Methods for the Generation of Mutagenic Phage Display Antibody Libraries for Affinity Maturation. International Journal of Molecular Sciences, 2019, 20, 1861.	1.8	30
495	Development of Whole-Porcine Monoclonal Antibodies with Potent Neutralization Activity against Classical Swine Fever Virus from Single B Cells. ACS Synthetic Biology, 2019, 8, 989-1000.	1.9	10
496	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. MBio, 2019, 10, .	1.8	17
497	Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	11
498	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	5.1	124

#	Article	IF	Citations
499	HIV-1 envelope proteins up-regulate N6-methyladenosine levels of cellular RNA independently of viral replication. Journal of Biological Chemistry, 2019, 294, 3249-3260.	1.6	32
500	Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. Journal of Virology, 2020, 94, .	1.5	15
501	Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. Vaccines, 2020, 8, 13.	2.1	18
502	Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of antiâ€“HIV-1 IgG1 antibodies in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18002-18009.	3.3	44
503	Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design. Current Topics in Microbiology and Immunology, 2020, 428, 31-87.	0.7	0
504	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles. Journal of Virology, 2020, 94, .	1.5	15
505	Vaccination Strategies Against Highly Variable Pathogens. Current Topics in Microbiology and Immunology, 2020, , .	0.7	1
506	A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. MBio, 2020, 11, .	1.8	27
507	Infectious disease antibodies for biomedical applications: A mini review of immune antibody phage library repertoire. International Journal of Biological Macromolecules, 2020, 163, 640-648.	3.6	17
508	Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies. Journal of Immunological Methods, 2020, 479, 112764.	0.6	13
509	Broadly Neutralizing Antibodies for HIV Prevention. Annual Review of Medicine, 2020, 71, 329-346.	5.0	49
510	Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein. AIDS Research and Human Retroviruses, 2021, , .	0.5	0
511	CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection. Frontiers in Immunology, 2021, 12, 708355.	2.2	5
512	Endocytic Motif on a Biotin-Tagged HIV-1 Env Modulates the Co-Transfer of Env and Gag during Cell-to-Cell Transmission. Viruses, 2021, 13, 1729.	1.5	3
513	Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis. Frontiers in Immunology, 2021, 12, 734304.	2.2	9
514	Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward. Vaccines, 2021, 9, 1001.	2.1	2
515	Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies. Vavilovskii Zhurnal Genetiki I Selektsii, 2021, 25, 562-572.	0.4	1
516	Modern Antibody Technology: The Impact on Drug Development. , 0, , 1147-1186.		25

#	Article	IF	Citations
517	Phage display. Annual Reports in Combinatorial Chemistry and Molecular Diversity, 1997, , 210-262.	0.4	5
518	Novel Hiv Neutralizing Antibodies Selected from Phage Display Libraries. , 2004, , 105-117.		2
519	PJUFO: a Phagemid for Display of cDNA Libraries on Phage Surface Suitable for Selective Isolation of Clones Expressing Allergens. Advances in Experimental Medicine and Biology, 1996, 409, 103-110.	0.8	22
520	Genetically Engineered Antitumor Monoclonal Antibodies. , 1995, , 393-432.		2
521	Applying Genetic Engineering to the Structural Analysis of Proteins. Pharmaceutical Biotechnology, 1995, 7, 329-350.	0.3	1
522	Affinity Isolation of Antigen-Specific Circulating B Cells for Generation of Phage Display-Derived Human Monoclonal Antibodies. Methods in Molecular Biology, 2009, 562, 37-43.	0.4	4
523	Combinatorial chemistry: Mixture-based combinatorial libraries of acyclic and heterocyclic compounds from amino acids and short peptides. , 2003, , 109-123.		3
524	The Combinatorial Approach to Human Antibodies. Handbook of Experimental Pharmacology, 1994, , 243-266.	0.9	1
525	Production of Human Monoclonal Antibodies Against Rabies Virus. Current Topics in Microbiology and Immunology, 1994, 187, 195-205.	0.7	10
526	Intrabodies as Antiviral Agents. Current Topics in Microbiology and Immunology, 2001, 260, 247-270.	0.7	21
527	Designing Intrabodies: Structural Features and the Use of Intracellular Trafficking Signals. , 1998, , 1-22.		1
528	Synthetic Antibody Engineering: Concepts and Applications. , 2018, , 81-100.		1
529	Monoclonal Antibodies from Display Libraries. , 2004, , 511-531.		3
530	Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system.. Journal of Biological Chemistry, 1992, 267, 16007-16010.	1.6	177
531	Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1793-8.	3.3	54
532	Effect of Natural HIV-1 Envelope V1-V2 Sequence Diversity on the Binding of V3-Specific and Non-V3-Specific Antibodies. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 69-73.	0.3	15
533	Development of an HIV-1 Reference Panel of Subtype B Envelope Clones Isolated From the Plasma of Recently Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 1-11.	0.9	41
534	Selection of human anti-human immunodeficiency virus type 1 envelope single-chain antibodies from a peripheral blood cell-based phage repertoire.. Journal of General Virology, 1998, 79, 2883-2894.	1.3	7

#	Article	IF	Citations
535	Human recombinant Puumala virus antibodies: cross-reaction with other hantaviruses and use in diagnostics.. Journal of General Virology, 1998, 79, 659-665.	1.3	20
536	Human neutralizing human immunodeficiency virustype 2-specific Fab molecules generated by phage display. Journal of General Virology, 1999, 80, 1987-1993.	1.3	13
537	Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. Journal of General Virology, 2000, 81, 2451-2459.	1.3	74
538	An immunodominant neutralization epitope on the â€˜thumbâ€™ subdomain of human immunodeficiency virus type 1 reverse transcriptase revealed by phage display antibodies. Journal of General Virology, 2001, 82, 813-820.	1.3	6
539	Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists. Journal of General Virology, 2016, 97, 2427-2440.	1.3	11
540	Phage and Yeast Display. , 0, , 103-127.		2
541	Preparation of Recombinant Human Monoclonal Antibody Fab Fragments Specific forEntamoeba histolytica. Vaccine Journal, 1999, 6, 383-387.	2.6	16
542	Human Fab fragments specific for the Haemophilus influenzae b polysaccharide isolated from a bacteriophage combinatorial library use variable region gene combinations and express an idiotype that mirrors in vivo expression. Infection and Immunity, 1997, 65, 261-266.	1.0	36
543	Detection and typing of herpes simplex viruses by using recombinant immunoglobulin fragments produced in bacteria. Journal of Clinical Microbiology, 1997, 35, 1504-1509.	1.8	15
544	Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of Virology, 1994, 68, 4821-4828.	1.5	441
545	Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. Journal of Virology, 1995, 69, 4413-4422.	1.5	334
546	Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles. Journal of Virology, 1996, 70, 6557-6562.	1.5	6
547	In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope. Journal of Virology, 1996, 70, 9046-9050.	1.5	51
548	Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. Journal of Virology, 1997, 71, 8289-8298.	1.5	58
549	Phage-displayed peptide targeting on the Puumala hantavirus neutralization site. Journal of Virology, 1997, 71, 3879-3885.	1.5	23
550	Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. Journal of Virology, 1997, 71, 6869-6874.	1.5	79
551	Simian Immunodeficiency Virus (SIV) Envelope-Specific Fabs with High-Level Homologous Neutralizing Activity: Recovery from a Long-Term-Nonprogressor SIV-Infected Macaque. Journal of Virology, 1998, 72, 585-592.	1.5	39
552	Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1. Journal of Virology, 1998, 72, 10270-10274.	1.5	68

#	Article	IF	Citations
553	Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity. Journal of Virology, 1998, 72, 3512-3519.	1.5	182
554	Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies. Journal of Virology, 1998, 72, 6332-6338.	1.5	135
555	Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120. Journal of Virology, 1999, 73, 4360-4371.	1.5	122
556	Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection. Journal of Virology, 1999, 73, 6024-6030.	1.5	268
557	Protein-protein interactions: methods for detection and analysis. Microbiological Reviews, 1995, 59, 94-123.	10.1	715
558	Superantigen properties of a human sialoprotein involved in gut-associated immunity.. Journal of Clinical Investigation, 1995, 96, 417-426.	3.9	50
559	HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. Journal of Clinical Investigation, 2017, 127, 4352-4364.	3.9	17
560	Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. PLoS Medicine, 2006, 3, e255.	3.9	72
561	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	1.1	137
562	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. PLoS ONE, 2014, 9, e114709.	1.1	11
563	Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein. PLoS ONE, 2016, 11, e0156798.	1.1	19
564	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	1.1	24
565	HIV-1 Vaccine Strategies Utilizing Viral Vectors Including Antigen- Displayed Inoviral Vectors. Current HIV Research, 2014, 11, 610-622.	0.2	2
566	Phage Display on the Base of Filamentous Bacteriophages: Application for Recombinant Antibodies Selection. Acta Naturae, 2009, 1, 20-28.	1.7	31
567	Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response. Acta Naturae, 2015, 7, 11-21.	1.7	19
568	Bacterial expression of a neutralizing mouse monoclonal antibody Fab fragment to a 150-kilodalton surface antigen of Entamoeba histolytica.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 35-40.	0.6	15
569	The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1+ lymph node macrophages. ELife, 2015, 4, .	2.8	19
570	Uncovering the basis of protein-protein interaction specificity with a combinatorially complete library. ELife, 2020, 9, .	2.8	48

#	Article	IF	Citations
571	Mechanisms and in-vivo Significance of HIV-1 Neutralisation. , 2000, , 99-132.		0
572	New Directions in Immunopharmacotherapy. , 2000, , 315-346.		0
573	Applications for Purification and Screening. , 2000, , 173-194.		0
576	Current topics in AIDS vaccine development. Drug Delivery System, 2010, 25, 46-51.	0.0	0
577	Genetically Engineered Antibodies. , 1993, , 625-639.		1
578	Recombinant Therapeutic Human Monoclonal Antibodies. Handbook of Experimental Pharmacology, 1994, , 23-48.	0.9	0
579	Herstellung von humanen monoklonalen AntikÃ¶rpern in vitro durch Repertoir- Klonierung. Ersatz- Und ErgÃnzungsmethoden Zu Tierversuchen, 1995, , 301-306.	0.0	0
580	MonoklonaleAntikÃ¶rpertechnik. , 1997, , 145-194.		0
581	Phage Libraries for Generation of Single Chain Fv Antibodies for Intracellular Immunization. , 1998, , 23-46.		0
582	Monoclonal Antibodies and Their Engineered Fragmen.... The Electrical Engineering Handbook, 1999, , .	0.2	1
584	Molecular biology and immunology revolutionize chemistry, or how to guide the evolution of proteins for the benefit of humanity. Visnik Nacional Noi Academii Nauk Ukrai Ni, 2019, , 69-85.	0.0	0
585	Use of Monoclonal Antibodies to Prevent the Sexual Transmission of Human Immunodeficiency Virus Type 1. Current Immunology Reviews, 2019, 15, 123-130.	1.2	1
607	Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Molecular Medicine, 1998, 4, 384-91.	1.9	17
609	Phage display on the base of filamentous bacteriophages: application for recombinant antibodies selection. Acta Naturae, 2009, 1, 20-8.	1.7	11
610	Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response. Acta Naturae, 2015, 7, 11-21.	1.7	12
611	Analysis of variants associated with abnormal drug responses, genetics, and genomics in drug design. , 2022, , 209-235.		0
612	So Pathogenic or So What?â€"A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research. Viruses, 2022, 14, 135.	1.5	5
613	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. Nature Communications, 2022, 13, 732.	5.8	19

#	Article	IF	Citations
614	HIV vaccines: progress to date. Drugs, 2011, 71, 387-414.	4.9	41
615	Dual Role of HIV-1 Envelope Signal Peptide in Immune Evasion. Viruses, 2022, 14, 808.	1.5	0
618	Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env. PLoS Pathogens, 2022, 18, e1010531.	2.1	3
619	Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. IScience, 2022, 25, 104449.	1.9	16
620	Synthetic libraries of immune cells displaying a diverse repertoire of chimaeric antigen receptors as a potent cancer immunotherapy. Nature Biomedical Engineering, 2022, 6, 842-854.	11.6	4
622	Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors. Immunity, 2022, 55, 2149-2167.e9.	6.6	21
623	A new dawn for monoclonal antibodies against antimicrobial resistant bacteria. Frontiers in Microbiology, 0, 13, .	1.5	5
624	Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.. Journal of Immunology, 1995, 154, 893-906.	0.4	82
625	Construction of a Fab Library Merging Chains from Semisynthetic and Immune Origin, Suitable for Developing New Tools for Gluten Immunodetection in Food. Foods, 2023, 12, 149.	1.9	3
627	Antibody Isolation from Human Synthetic Libraries of Single-Chain Antibodies and Analysis Using NGS. Methods in Molecular Biology, 2023, , 347-372.	0.4	0